We narrowed to 1,055 results for: MAL

#35512-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry (#35512). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin E123T/T159C mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Nov. 13, 2025

Academic Institutions and Nonprofits only

#104052-AAVPHP.V1

Ready-to-use AAV PHP.V1 particles produced from pAAV-CAG-DIO-EYFP (#104052). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-EYFP plasmid DNA. CAG-driven, Cre-dependent expression of EYFP. These AAV were produced with the PHP.V1 serotype, which permits efficient transduction of brain vascular cells. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

July 24, 2020

Academic Institutions and Nonprofits only

#200778-AAV8

Ready-to-use AAV8 particles produced from AAV-∆Hapln1 (#200778). In addition to the viral particles, you will also receive purified AAV-∆Hapln1 plasmid DNA. Syn-driven, HAPLN1(delta40-154)-cfGFP expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#200777-AAV8

Ready-to-use AAV8 particles produced from AAV-HAPLN1 (#200777). In addition to the viral particles, you will also receive purified AAV-HAPLN1 plasmid DNA. Syn-driven, HAPLN1-cfGFP expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#200773-AAV8

Ready-to-use AAV8 particles produced from AAV-cfGFP (#200773). In addition to the viral particles, you will also receive purified AAV-cfGFP plasmid DNA. Syn-driven, cysteine-free GFP (cfGFP) expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#99130-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Sept. 18, 2019

Academic Institutions and Nonprofits only

#35497-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO C1V1 (t/t)-TS-EYFP (#35497). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO C1V1 (t/t)-TS-EYFP plasmid DNA. EFIa-driven, Cre-dependent, C1V1 (t/t) fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Yizhar et al Nature. 2011 Jul 27;477(7363):171-8. doi

March 30, 2018

Academic Institutions and Nonprofits only

#218879-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-flex-iGABASnFR2(no bind)-WPRE (#218879). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2(no bind)-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor control iGABASnFR2(no bind) (no change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Oct. 21, 2024

Academic Institutions and Nonprofits only

#123308-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-GRAB_NE1m (#123308). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_NE1m plasmid DNA. Synapsin-driven expression of GRAB-NE1 norepinephrine sensor. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Feng et al Neuron. 2019 May 22;102(4):745-761.e8. d

Nov. 4, 2019

Academic Institutions and Nonprofits only

#159605-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-NIR-GECO2G (#159605). In addition to the viral particles, you will also receive purified pAAV-CAG-NIR-GECO2G plasmid DNA. CAG-driven expression of the near-infrared calcium indicator NIR-GECO2G. These AAV preparations are suitable purity for injection into animals.

Robert Campbell

Qian et al PLoS Biol. 2020 Nov 24;18(11):e3000965.

Dec. 18, 2024

Academic Institutions and Nonprofits only

#98928-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAG.Flex.Ruby2sm-Flag.WPRE.SV40 (#98928). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.Ruby2sm-Flag.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent expression of Ruby2sm-Flag spaghetti monster construct. Spaghetti monster constructs are not fluorescent ("dark") to allow full range of antibody staining. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Viswanathan et al Nat Methods. 2015 Jun;12(6):568-76. doi:

Oct. 29, 2025

Academic Institutions and Nonprofits only

#218879-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-flex-iGABASnFR2(no bind)-WPRE (#218879). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2(no bind)-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor control iGABASnFR2(no bind) (no change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Oct. 21, 2024

Academic Institutions and Nonprofits only

#112004-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mKate2 (#112004). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mKate2 plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor and bicistronic mKate2 expression. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Feb. 14, 2022

Academic Institutions and Nonprofits only

#44361-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-DIO-hM3D(Gq)-mCherry (#44361). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-hM3D(Gq)-mCherry plasmid DNA. Syn-driven, Cre-dependent, hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Krashes et al J Clin Invest. 2011 Apr;121(4):1424-8. d

Oct. 11, 2017

Academic Institutions and Nonprofits only

#59171-AAV1

Ready-to-use AAV1 particles produced from pAAV-Syn-ChrimsonR-tdT (#59171). In addition to the viral particles, you will also receive purified pAAV-Syn-ChrimsonR-tdT plasmid DNA. Syn-driven ChrimsonR-tdTomato expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Feb. 7, 2018

Academic Institutions and Nonprofits only

#59171-AAV9

Ready-to-use AAV9 particles produced from pAAV-Syn-ChrimsonR-tdT (#59171). In addition to the viral particles, you will also receive purified pAAV-Syn-ChrimsonR-tdT plasmid DNA. Syn-driven ChrimsonR-tdTomato expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Feb. 7, 2018

Academic Institutions and Nonprofits only

#162375-AAV9

Ready-to-use AAV9 particles produced from pGP-AAV-syn-jGCaMP8m-WPRE (#162375). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP8m-WPRE plasmid DNA. Syn-driven expression of calcium sensor GCaMP8m (faster, more sensitive). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

June 22, 2021

Academic Institutions and Nonprofits only

#59170-AAV5

Ready-to-use AAV5 particles produced from pAAV-Syn-Chronos-GFP (#59170). In addition to the viral particles, you will also receive purified pAAV-Syn-Chronos-GFP plasmid DNA. Syn-driven Chronos-GFP expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

July 21, 2017

Academic Institutions and Nonprofits only

#44362-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-DIO-hM4D(Gi)-mCherry (#44362). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-hM4D(Gi)-mCherry plasmid DNA. Syn-driven, Cre-dependent, hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Krashes et al J Clin Invest. 2011 Apr;121(4):1424-8. d

June 21, 2017

Academic Institutions and Nonprofits only

#44361-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-hSyn-DIO-hM3D(Gq)-mCherry (#44361). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-hM3D(Gq)-mCherry plasmid DNA. Syn-driven, Cre-dependent, hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV were produced with the PHP.eB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Krashes et al J Clin Invest. 2011 Apr;121(4):1424-8. d

March 22, 2018

Academic Institutions and Nonprofits only